Biomarkers of Host Physiological Response During Recurrent Febrile Episodes

Abstract

Recurrent febrile episodes represent a diagnostic and management challenge in clinical practice, particularly due to the heterogeneous etiologies and the complex interplay between infectious and autoinflammatory processes. The identification and utilization of host physiological biomarkers have emerged as a pivotal strategy in differentiating underlying causes, monitoring disease activity, and guiding therapeutic decisions. This review synthesizes recent PubMed-indexed evidence on key biomarkers implicated in the host response during recurrent fever, examines their pathophysiological roles, evaluates their clinical utility, and discusses guideline-driven recommendations for their application in practice.

Introduction

Recurrent fever, defined as repeated episodes of elevated body temperature separated by intervals of normothermia, often signals underlying systemic disorders such as autoinflammatory syndromes, periodic fever syndromes, or recurrent infections. The diagnostic complexity is compounded by overlapping clinical presentations and the absence of pathognomonic features in many cases. Biomarkers that reflect the host physiological response offer critical insights into the mechanisms driving these febrile episodes and serve as objective tools to enhance diagnostic precision, risk stratification, and treatment monitoring. In this article, we explore the landscape of established and emerging biomarkers relevant to recurrent febrile states, emphasizing their pathophysiological significance and clinical applicability.

Epidemiology / Disease Burden

Recurrent febrile episodes are encountered across age groups, but are particularly prevalent in pediatric populations, where they account for a significant proportion of outpatient visits and hospital admissions. Conditions such as Familial Mediterranean Fever (FMF), Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis (PFAPA) syndrome, and other hereditary periodic fevers contribute to the disease burden. Epidemiological data reveal that recurrent fever syndromes may be underdiagnosed due to lack of awareness and diagnostic challenges, leading to delays in appropriate management and increased morbidity. The global burden is further magnified in regions with endemic infectious diseases, where recurrent infections augment the complexity of clinical evaluation.

Pathophysiology

The physiological response to recurrent febrile episodes is orchestrated by a network of immune mediators and cellular pathways. Infections trigger the production of exogenous pyrogens such as microbial toxins, which in turn stimulate endogenous pyrogens including interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). These cytokines act on the hypothalamic thermoregulatory center to induce fever. In autoinflammatory syndromes, genetic mutations in the inflammasome pathway (e.g., MEFV, NLRP3, TNFRSF1A) result in inappropriate activation of innate immunity and excessive cytokine release. Biomarkers such as C-reactive protein (CRP), serum amyloid A (SAA), procalcitonin, and ferritin reflect the magnitude and nature of the host response, with distinct patterns noted in infectious versus autoinflammatory contexts. Understanding these mechanisms guides the rational use of biomarker testing in clinical practice.

Risk Factors

Risk factors for recurrent febrile episodes vary according to underlying etiology. Genetic predispositions, such as mutations in genes encoding inflammasome components or cytokine receptors, are prominent in hereditary periodic fever syndromes. Immunodeficiency states, both congenital and acquired, increase susceptibility to recurrent infections. Environmental factors, including exposure to endemic pathogens, poor sanitation, and malnutrition, further contribute in certain populations. In the clinical context, a thorough risk assessment incorporating family history, epidemiological exposures, and comorbidities is essential to guide targeted diagnostic evaluation.

Clinical Features

Recurrent fever syndromes present with episodic high-grade fevers, often accompanied by constitutional symptoms such as malaise, myalgia, and fatigue. Specific syndromic features—such as serositis in FMF, aphthous ulcers in PFAPA, or urticarial rash in cryopyrin-associated periodic syndromes—can aid in clinical differentiation. The temporal pattern of fever (duration, frequency, and periodicity), associated systemic symptoms, and response to empiric therapies provide important diagnostic clues. Biomarker profiles may correlate with disease activity and guide the clinician in distinguishing between infectious, inflammatory, and malignant etiologies.

Diagnosis

The diagnostic algorithm for recurrent febrile episodes integrates detailed clinical assessment with selective laboratory investigations. Core biomarkers include CRP, erythrocyte sedimentation rate (ESR), procalcitonin, and SAA, each providing complementary information about the inflammatory milieu. Procalcitonin is particularly useful in discriminating bacterial from viral or autoinflammatory causes. Advanced markers such as IL-18, interferon-gamma (IFN-γ), and genetic testing for periodic fever syndromes have expanded the diagnostic armamentarium. Serial biomarker measurements can help document disease flares, monitor response to therapy, and detect complications such as amyloidosis (elevated SAA). Imaging and organ function tests may be warranted based on clinical suspicion.

Treatment & Management

Management strategies are tailored to the underlying etiology and informed by biomarker-guided assessment of disease activity. In autoinflammatory syndromes, cytokine-targeted therapies such as IL-1 inhibitors (anakinra, canakinumab) and colchicine are mainstays, with biomarker normalization serving as a therapeutic endpoint. In infectious causes, appropriate antimicrobial therapy is guided by clinical and laboratory findings, including procalcitonin trends. Regular monitoring of acute phase reactants supports early detection of relapse or complications. Multidisciplinary care, patient education, and genetic counseling are integral components of comprehensive management.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advancements in the identification and application of novel biomarkers using proteomics, transcriptomics, and metabolomics platforms. Biomarkers such as S100A8/A9 (calprotectin), IL-18, and specific microRNAs are being investigated for their potential to enhance diagnostic specificity and prognostication in autoinflammatory and infectious syndromes. High-throughput sequencing and multiplex cytokine assays are facilitating earlier and more precise diagnosis. Targeted biologic therapies, guided by biomarker profiling, are reshaping the therapeutic landscape of recurrent fever syndromes, offering improved outcomes with reduced toxicity profiles.

Guideline Recommendations

Professional society guidelines, including those from the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR), underscore the importance of integrating biomarker assessment into the diagnostic and therapeutic algorithms for recurrent fever. Recommendations include baseline and serial measurement of CRP, SAA, ESR, and procalcitonin in patients with suspected autoinflammatory or infectious etiologies. Molecular diagnostic testing for hereditary fever syndromes is advised in selected cases with suggestive clinical features. The use of biomarkers to monitor treatment response and guide the escalation or de-escalation of immunomodulatory therapy is widely endorsed.

Conclusion

The strategic application of host physiological biomarkers has revolutionized the approach to recurrent febrile episodes, enabling clinicians to unravel complex pathophysiological processes, achieve timely and accurate diagnoses, and optimize patient outcomes. Ongoing research into novel biomarkers and precision medicine approaches holds promise for further enhancing the management of this challenging clinical entity. Clinicians should remain abreast of evolving evidence and incorporate guideline-driven biomarker strategies to deliver individualized, evidence-based care.